Tags : P-IIIa

Sanofi and Regeneron Report Positive Results of Dupixent (dupilumab) in

Shots: The P-IIIa Dupixent Eosinophilic Esophagitis study involves assessing Dupixent (N=42) (300mg weekly) v/s PBO (N=39) in 81 patients aged 12 years and older with eosinophilic esophagitis (EoE). In addition, enrolling patients for P-IIIb for extended active treatment period to continue in 28wks The P-II study results: met its co-1EPs and 2EPs in DSQ baseline […]Read More